Clinical trials
Idiopathic Pulmonary Fibrosis clinical trials
Below are recruiting idiopathic pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 85 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07284459RecruitingPhase 2
Testing PIPE 791 for idiopathic pulmonary fibrosis
This trial tests an investigational drug called PIPE 791 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug slows lung function decline, and you may continue your current IPF medicine.
Mar del Plata, Buenos AiresAges 40 years+ - NCT03120481Recruiting
Check how respiratory health changes in people without lung problems
This trial enrolls adults who recently had a chest X-ray as part of routine health screening and did not show major abnormal findings, and who do not have significant breathing symptoms. It may help researchers understand changes in respiratory health over time and improve how respiratory disease risk is monitored.
Seoul, SeoulAges 19–90 - NCT04160715Recruiting
Registry for people with idiopathic pulmonary fibrosis in Korea
This study is a registry that collects health information from people diagnosed with idiopathic pulmonary fibrosis (IPF). It may help researchers better understand IPF and how it changes over time, even if it doesn’t involve a new medication.
Seongnam-siAges 30–100 - NCT06189820RecruitingPhase 2
FAP protein as a marker for fibrotic lung disease
This trial is looking at a protein called FAP in the blood of people with fibrotic lung diseases. It aims to understand how this protein might be used as a marker to help doctors better diagnose and track these conditions.
BrusselsAges 18 years+ - NCT07868419RecruitingPhase 3
Nalbuphine tablets for chronic cough in pulmonary fibrosis
This trial tests an extended-release tablet called nalbuphine to reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring and often leads to a persistent cough. If you have IPF and have been coughing for at least 8 weeks, this study may help manage that symptom.
Wilmington, DelawareAges 40 years+ - NCT07820254Recruiting
How well people with pulmonary fibrosis can breathe in
This study looks at how well people with pulmonary fibrosis can breathe in and aims to see if their breathing flow rate is linked to their condition. It may help doctors understand more about the disease and plan better care.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07790614Recruiting
Comparing two CT scan methods for identifying pulmonary fibrosis
This study compares two types of CT scans to see which one is better at identifying idiopathic pulmonary fibrosis (IPF), a specific type of interstitial lung disease. You may be able to join if you have been diagnosed with ILD and are being discussed by a team of specialists.
Rozzano, ItalyAges 18 years+ - NCT06323876Recruiting
Using CT scans to personalize treatment for pulmonary fibrosis
This study uses detailed CT scans to find better ways to treat idiopathic pulmonary fibrosis (IPF). It may help doctors choose the right treatment for each person.
Charlottesville, VirginiaAges 40–101 - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT07707245Recruiting
Finding biomarkers in lung disease and lung cancer
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
Milan, MilanAges 18 years+ - NCT07687459RecruitingPhase 3
Oral treatment for idiopathic pulmonary fibrosis
This trial tests an experimental pill called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. The study aims to see if the drug can slow down the disease and improve breathing.
Hefei, AnhuiAges 40 years+ - NCT07679893RecruitingPhase 2
Inhaled nintedanib for idiopathic pulmonary fibrosis
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Windsor, OntarioAges 40–80 - NCT07671911RecruitingPhase 3
Cough relief for pulmonary fibrosis
This trial tests a new extended-release medicine, nalbuphine, to reduce chronic coughing in people with idiopathic pulmonary fibrosis (a lung disease that scars the lungs). It may help make cough less frequent and less bothersome.
Newport Beach, CaliforniaAges 40 years+ - NCT06125327RecruitingPhase 2/Phase 3
SC1011 for idiopathic pulmonary fibrosis (IPF)
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
Beijing, Beijing MunicipalityAges 40–80 - NCT06702228Recruiting
Precision care for pulmonary fibrosis in Ireland
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
DublinAges 18–85 - NCT07516951RecruitingPhase 2
Study of zampilimab for idiopathic pulmonary fibrosis
This trial tests an investigational drug called zampilimab for people with idiopathic pulmonary fibrosis (IPF). It aims to find a safe and effective dose that may slow lung function decline.
Hannibal, MissouriAges 40 years+ - NCT07486206Recruiting
Optimizing follow-up for interstitial lung disease
This trial tests a new way to organize follow-up visits for people with interstitial lung disease (a group of lung conditions). It aims to make care simpler and more effective for patients who are already on treatment.
Granollers, BarcelonaAges 18 years+ - NCT07464912RecruitingPhase 3
Testing TDI01 for idiopathic pulmonary fibrosis
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
Beijing, Beijing MunicipalityAges 40–80 - NCT07466420Recruiting
Quercetin for fibrotic lung disease
This trial tests whether taking quercetin, a natural supplement, can help people with fibrotic interstitial lung diseases (a group of conditions that cause scarring in the lungs). If you have been diagnosed with idiopathic pulmonary fibrosis (IPF) or another fibrotic ILD and are on standard treatments, you may be able to join.
Heraklion, CreteAges 18 years+ - NCT07447102RecruitingPhase 2
Study of BC006 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
Shanghai, Shanghai MunicipalityAges 40 years+ - NCT07332117Recruiting
Studying body changes in IPF and PPF patients starting anti-fibrotic drugs
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
LondonAges 18 years+ - NCT07312305Recruiting
Small airways test in idiopathic pulmonary fibrosis
This study measures how well the small airways in your lungs work if you have idiopathic pulmonary fibrosis (IPF). It aims to find better ways to assess the disease and could lead to improved care.
Milan, LombardyAges 18 years+ - NCT07299695RecruitingPhase 3
IVIG for sudden worsening of IPF
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
PátraiAges 18 years+ - NCT07284602RecruitingPhase 3
Comparing a new drug to pirfenidone for lung scarring
This trial tests a new medicine, LYT-100 (deupirfenidone), against the standard drug pirfenidone for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the new drug works better or has fewer side effects.
Palm Spring, CaliforniaAges 40 years+
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Idiopathic Pulmonary Fibrosis trials by city
Studies with a site in or near these metro areas.
Idiopathic Pulmonary Fibrosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for idiopathic pulmonary fibrosis?
- Yes. Clin2 currently lists 85 recruiting idiopathic pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.